Opportunities for drug sponsors to integrate randomized controlled clinical trials into routine clinical practice may be fairly limited, according to a new US Food and Drug Administration draft guidance.
Key Takeaways
-
Integrating clinical trials into routine practice could make participation easier for patients, improve diversity of enrollment and thus make study results more generalizable, FDA says.
-
Trials most appropriate for integration into clinical practice are those with streamlined protocols and procedures that focus on essential data collection including trials that are sometimes referred to as point of care trials, or large simple trials
The 17 September draft emphasizes that this trial design approach will typically only work for already approved drugs being studied for new
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?